Literature DB >> 12044382

Persistence of dual-tropic HIV-1 in an individual homozygous for the CCR5 Delta 32 allele.

Paul R Gorry1, Chengsheng Zhang, Sam Wu, Kevin Kunstman, Elizabeth Trachtenberg, John Phair, Steven Wolinsky, Dana Gabuzda.   

Abstract

Entry of HIV-1 into a cell happens only after viral envelope glycoproteins have bound to CD4 and a chemokine receptor. Generally, macrophage-tropic strains use CCR5, and T cell-line-tropic strains use CXCR4 as coreceptors for virus entry. Dual-tropic viruses can use both CCR5 and CXCR4. About 1% of white people are homozygous for a non-functional CCR5 allele, containing a 32 base pair deletion (CCR5 Delta 32). We studied the persistence of dual-tropic HIV-1 in an individual homozygous for this deletion. Our results suggest that structural features of the HIV-1 envelope linked to CCR5 tropism could confer a selective advantage in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12044382     DOI: 10.1016/S0140-6736(02)08681-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  28 in total

1.  Primary infection by a human immunodeficiency virus with atypical coreceptor tropism.

Authors:  Chunlai Jiang; Nicholas F Parrish; Craig B Wilen; Hui Li; Yue Chen; Jeffrey W Pavlicek; Anna Berg; Xiaozhi Lu; Hongshuo Song; John C Tilton; Jennifer M Pfaff; Elizabeth A Henning; Julie M Decker; M Anthony Moody; Mark S Drinker; Robert Schutte; Stephanie Freel; Georgia D Tomaras; Rebecca Nedellec; Donald E Mosier; Barton F Haynes; George M Shaw; Beatrice H Hahn; Robert W Doms; Feng Gao
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

Review 2.  Chemokines in Wound Healing and as Potential Therapeutic Targets for Reducing Cutaneous Scarring.

Authors:  Peter Adam Rees; Nicholas Stuart Greaves; Mohamed Baguneid; Ardeshir Bayat
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-11-01       Impact factor: 4.730

3.  Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote.

Authors:  Paul R Gorry; Rebecca L Dunfee; Megan E Mefford; Kevin Kunstman; Tom Morgan; John P Moore; John R Mascola; Kristin Agopian; Geoffrey H Holm; Andrew Mehle; Joann Taylor; Michael Farzan; Hui Wang; Philip Ellery; Samantha J Willey; Paul R Clapham; Steven M Wolinsky; Suzanne M Crowe; Dana Gabuzda
Journal:  Virology       Date:  2007-01-18       Impact factor: 3.616

4.  CCR5Delta32 59537-G/A promoter polymorphism is associated with low translational efficiency and the loss of CCR5Delta32 protective effects.

Authors:  Qingwen Jin; Lokesh Agrawal; L Meyer; R Tubiana; Ioannis Theodorou; Ghalib Alkhatib
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

5.  Counterpoint: Cord blood stem cell therapy for acquired immune deficiency syndrome.

Authors:  Ghalib Alkhatib
Journal:  Stem Cells Dev       Date:  2009 Jan-Feb       Impact factor: 3.272

Review 6.  Early events of HIV-1 infection: can signaling be the next therapeutic target?

Authors:  Kate L Jones; Redmond P Smyth; Cândida F Pereira; Paul U Cameron; Sharon R Lewin; Anthony Jaworowski; Johnson Mak
Journal:  J Neuroimmune Pharmacol       Date:  2011-03-05       Impact factor: 4.147

7.  Cancer: A most exceptional response.

Authors:  Vivien Marx
Journal:  Nature       Date:  2015-04-16       Impact factor: 49.962

8.  Constrained use of CCR5 on CD4+ lymphocytes by R5X4 HIV-1: efficiency of Env-CCR5 interactions and low CCR5 expression determine a range of restricted CCR5-mediated entry.

Authors:  Lamorris M Loftin; Martha F Kienzle; Yanjie Yi; Benhur Lee; Fang-Hua Lee; Lachlan Gray; Paul R Gorry; Ronald G Collman
Journal:  Virology       Date:  2010-04-09       Impact factor: 3.616

9.  Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 allele.

Authors:  Lachlan Gray; Melissa J Churchill; Niamh Keane; Jasminka Sterjovski; Anne M Ellett; Damian F J Purcell; Pantelis Poumbourios; Chenda Kol; Bin Wang; Nitin K Saksena; Steven L Wesselingh; Patricia Price; Martyn French; Dana Gabuzda; Paul R Gorry
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

10.  Maraviroc in the treatment of HIV infection.

Authors:  Neelanjana Ray
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.